1221398-11-3

Basic information

• Product Name: 6-Chloro-5-iodopyridin-2-aMine
• Synonyms: 6-Chloro-5-iodopyridin-2-aMine;6-Chloro-5-iodo-pyridin-2-ylaMine;1221398-11-3 6-Chloro-5-iodopyridin-2-amine
• CAS NO: 1221398-11-3
• Molecular Formula: C₅H₄ClIN₂
• Molecular Weight: 254.45613
• Mol File: 1221398-11-3.mol

Chemical Properties

• Boiling Point: 340.4±42.0 °C(Predicted)
• Appearance: /
• Density: 2.139±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.12±0.10(Predicted)
• CAS DataBase Reference: 6-Chloro-5-iodopyridin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-5-iodopyridin-2-aMine(1221398-11-3)
• EPA Substance Registry System: 6-Chloro-5-iodopyridin-2-aMine(1221398-11-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN2811
• Hazardous Substances Data: 1221398-11-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
6-Chloro-5-iodopyridin-2-amine is used as a reagent in pharmaceutical research for its ability to facilitate the synthesis of a variety of compounds. Its dual halogen structure makes it a versatile building block in the development of new drugs and pharmaceutical agents.
Used in Chemical Synthesis:
In the field of chemical synthesis, 6-Chloro-5-iodopyridin-2-amine is employed as an intermediate. Its reactivity with the halogens chlorine and iodine allows for the creation of a broad spectrum of chemical products, making it a valuable component in the synthesis process.
Used in Research and Development:
6-Chloro-5-iodopyridin-2-amine is utilized in research and development settings to explore its potential applications and reactions. Its unique structure and reactivity provide opportunities for scientists to investigate new pathways and outcomes in chemical reactions, potentially leading to innovative discoveries and applications.

Upstream product

• 45644-21-1 6-chloropyridin-2-amine 

Downstream Products

• 1621000-07-4 6-amino-2-phenylnicotinonitrile 

Relevant articles and documents

Method for preparing 6-chlorine-5-trifluoromethyl-2-aminopyridine

The invention provides a method for preparing 6-chlorine-5-trifluoromethyl-2-aminopyridine. According to the method, a product is obtained by taking 6-chlorine-5-iodine-2-aminopyridine as a raw material and adopting reaction steps such as amino protection, trifiuoroniethylation and deprotection.

FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

Ligand structure includes a new metal complexes

Compounds comprising a metal complex having novel ligands are provided. In particular, the compound is an iridium complex comprising novel aza DBX ligands. The compounds may be used in organic light emitting devices, particularly as emitting dopants, providing improved efficiency, low operating voltage, and long lifetime.

FACTOR XIa INHIBITORS

The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABAA receptor agonists

A series of 6-aminonicotinic acid analogues have been synthesized and pharmacologically characterized at native and selected recombinant GABA A receptors. 6-Aminonicotinic acid (3) as well as 2- and 4-alkylated analogues (9-11, 14-16) display low to mid-micromolar GABAAR binding affinities to native GABAA receptors (Ki 1.1-24 μM). The tetrahydropyridine analogue of 3 (22) shows low-nanomolar affinity (K i 0.044 μM) and equipotency as an agonist to GABA itself as well as the standard GABAA agonist isoguvacine. Cavities surrounding the core of the GABA binding pocket were predicted by molecular interaction field calculations and docking studies in a α1β 2γ2 GABAA receptor homology model, and were confirmed by affinities of substituted analogues of 3. The tight steric requirements observed for the remarkably few GABAAR agonists reported to date is challenged by our findings. New openings for agonist design are proposed which potentially could facilitate the exploration of different pharmacological profiles within the GABAAR area.

PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS

The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A2B adenosine receptor antagonists

The synthesis and SAR of a series of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent A2B adenosine receptor antagonists is described. Several compounds showed good selectivity versus other adenosine receptors. The potent and selective analogue 9 was shown to have good oral bioavailability in the rat.